Inavolisib联合来曲唑或氟维司群治疗PIK3CA突变、激素受体阳性、HER2阴性晚期或转移性乳腺癌(GO39374):一项开放标签、多中心、剂量递增和剂量扩展的1/1b期研究
这项1/1b期研究评估了Inavolisib联合内分泌治疗(±哌柏西利)在PIK3CA突变、HR阳性、HER2阴性晚期/转移性乳腺癌中的安全性和初步抗肿瘤活性,包括既往接受过CDK4/6抑制剂的患者。Inavolisib联合来曲唑组37例,联合氟维司群组60例;治疗相关不良事件发生率分别为94.6%和93.3%,多为低级别;确认客观缓解率分别为9.7%和25.9%,中位无进展生存期分别为3.7和7.3个月。
要点
- Inavolisib联合内分泌治疗在PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌中安全性可控。
- 联合来曲唑组和联合氟维司群组的确认客观缓解率分别为9.7%和25.9%。
- 在既往接受过CDK4/6抑制剂的患者中,两组的确认客观缓解率分别为13.0%和25.0%。
核心结论
- Inavolisib联合内分泌治疗在PIK3CA突变、HR阳性、HER2阴性晚期/转移性乳腺癌中显示出可控的安全性和令人鼓舞的初步抗肿瘤活性,包括CDK4/6抑制剂治疗后人群。
研究设计与样本
- 开放标签、多中心、剂量递增和剂量扩展的1/1b期研究,入组年龄≥18岁女性,接受Inavolisib(6 mg/9 mg口服每日一次)联合来曲唑(2.5 mg口服每日一次),或Inavolisib(9 mg口服每日一次)联合氟维司群(500 mg肌注,第1周期第1天和第15天,之后每4周一次),直至不可耐受毒性或疾病进展。
- 主要终点为安全性和耐受性。
- Inavolisib联合来曲唑组入组37例,Inavolisib联合氟维司群组入组60例。
主要发现
- 总体治疗相关不良事件发生率在Inavolisib联合来曲唑组为94.6%,在Inavolisib联合氟维司群组为93.3%,多为低级别;最常见(任一组≥10%患者)为高血糖、口腔炎、恶心和腹泻。
- 在可测量疾病患者中,确认客观缓解率在Inavolisib联合来曲唑组为9.7%,在Inavolisib联合氟维司群组为25.9%;中位无进展生存期分别为3.7个月和7.3个月。
- 在既往接受过CDK4/6抑制剂治疗的患者中(Inavolisib联合来曲唑组29/37例,Inavolisib联合氟维司群组58/60例),确认客观缓解率分别为13.0%和25.0%;中位无进展生存期分别为3.7个月和7.1个月。
- 未观察到任何研究治疗的药物-药物相互作用。
- 配对基线和第1周期第15天肿瘤活检及循环肿瘤DNA分析显示了研究治疗对药效学/病理生理反应生物标志物的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A variety of treatment options continue to be explored in the post-cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) setting for hormone receptor (HR)-positive, HER2-negative locally advanced/metastatic breast cancer (LA/mBC), and optimal sequencing of therapies remains to be determined. This phase 1/1b study examined inavolisib, a potent and selective PI3Kα inhibitor that promotes mutated p110α degradation, alone and in combination with endocrine therapy (ET) ± palbociclib, in PIK3CA-mutated, HR-positive, HER2-negative LA/mBC. We report data on inavolisib plus ET, including in patients who had previously received a CDK4/6i. METHODS: Women age ≥ 18 years received inavolisib (6 mg/9 mg orally once daily [PO QD]) plus letrozole (2·5 mg PO QD), or inavolisib (9 mg PO QD) plus fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1 then every 4 weeks), until unacceptable toxicity/disease progression. PRIMARY ENDPOINT: safety and tolerability. FINDINGS: Thirty-seven and 60 patients were enrolled in the inavolisib plus letrozole and inavolisib plus fulvestrant arms, respectively. Overall, treatment-related adverse events (mostly low grade) occurred in 94·6 % and 93·3 % of patients, respectively; the most frequent (≥10 % of patients in either arm) were hyperglycaemia, stomatitis, nausea, and diarrhoea. Confirmed objective response rates in patients with measurable disease were 9·7 % and 25·9 %, respectively; median progression-free survival was 3·7 and 7·3 months. Among patients with previous CDK4/6i therapy (29/37 and 58/60 patients, respectively), confirmed objective response rates were 13·0 % and 25·0 %; median progression-free survival was 3·7 and 7·1 months. No drug-drug interactions were observed for any study treatment. Paired baseline and Cycle 1 Day 15 tumour biopsies and circulating tumour DNA analyses demonstrated the impact of study treatment on pharmacodynamic/pathophysiologic biomarkers of response. INTERPRETATION: Inavolisib plus ET demonstrated a manageable safety profile and encouraging preliminary anti-tumour activity in patients with PIK3CA-mutated, HR-positive, HER2-negative LA/mBC, including those in the post-CDK4/6i setting.
引用
- Bedard PL, Jhaveri KL, Accordino MK, et al. Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. Eur J Cancer. 2025. PMID: 40203765. doi:10.1016/j.ejca.2025.115397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。